Halozyme Therapeutics (HALO) Asset Utilization Ratio (2011 - 2026)

Halozyme Therapeutics (HALO) has 16 years of Asset Utilization Ratio data on file, last reported at 0.58 in Q1 2026.

• Asset Utilization Ratio for Q1 2026 came in at 0.58, up 14.01% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.58 (up 14.01% YoY), and the FY2025 annual result was 0.61, up 13.81% from the prior year.
• Asset Utilization Ratio eased to 0.58 in Q1 2026 per HALO's latest filing, from 0.59 in the prior quarter.
• Over five years, Asset Utilization Ratio peaked at 0.59 in Q4 2025 and troughed at 0.32 in Q3 2022.
• A 5-year average of 0.46 and a median of 0.46 in 2024 frame the typical range for Asset Utilization Ratio.
• The sharpest annual moves came in 2022 and 2023: Asset Utilization Ratio retreated 23.94% in 2022, then jumped 33.1% in 2023.
• A 5-year view of Asset Utilization Ratio shows it stood at 0.36 in 2022, then grew by 28.4% to 0.46 in 2023, then advanced by 6.17% to 0.49 in 2024, then gained by 21.18% to 0.59 in 2025, then declined by 1.37% to 0.58 in 2026.
• Business Quant data shows HALO's Asset Utilization Ratio at 0.58 in Q1 2026, 0.59 in Q4 2025, and 0.58 in Q3 2025.